Dynavax Completes Phase 3 Study of HEPLISAV

Dynavax Technologies Corporation DVAX today reported completing the 12-month follow-up on all of the 2,449 subjects enrolled in its large-scale Phase 3 study of HEPLISAV evaluating immunogenicity in comparison to Engerix, lot-to-lot consistency and safety. With the study's completion, Dynavax said it expected to be in a position to report results within eight weeks.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDABiotechnologyHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!